High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma.
Cancer-associated fibroblasts
Cholangiocarcinoma
IL-33
Migration
Prognosis
Survival time
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
05
2020
accepted:
06
09
2020
entrez:
13
10
2020
pubmed:
14
10
2020
medline:
14
10
2020
Statut:
epublish
Résumé
Interleukin 33 (IL-33) promotes cholangiocarcinoma (CCA) genesis in a mouse model, however, its function in human CCA has not been clearly understood. This study was aimed to investigate IL-33 level in CCA tissues and its clinicopathological correlations. The results revealed that IL-33 was found in both cancer cells and stromal cancer-associated fibroblast (CAFs) staining patterns which were divided into high (CH) and low level (CL) in cancer cells; and presence (FP) and absence (FA) in CAFs. Kaplan-Meier analysis showed that patients in the CL group were significantly correlated with a short 2-year survival time (
Identifiants
pubmed: 33046978
doi: 10.7150/jca.48327
pii: jcav11p6571
pmc: PMC7545672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6571-6581Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Am J Med Sci. 2019 Oct;358(4):279-288
pubmed: 31420092
PLoS One. 2018 Mar 2;13(3):e0193428
pubmed: 29499051
Oncogene. 2015 Sep 17;34(38):4928-38
pubmed: 25531326
J Clin Invest. 2014 Jul;124(7):3241-51
pubmed: 24892809
Lung Cancer. 2015 Nov;90(2):346-51
pubmed: 26342550
Cancer Res. 2017 May 15;77(10):2735-2745
pubmed: 28249897
Cancer Lett. 2013 Jul 28;335(2):463-71
pubmed: 23499895
Nat Rev Immunol. 2016 Nov;16(11):676-689
pubmed: 27640624
Mol Med Rep. 2017 Oct;16(4):3887-3893
pubmed: 28765940
Cell Physiol Biochem. 2018;47(1):191-200
pubmed: 29763892
Proc Natl Acad Sci U S A. 2017 May 9;114(19):E3806-E3815
pubmed: 28439013
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Mol Biol (Mosk). 2019 Sep-Oct;53(5):774-789
pubmed: 31661477
Int J Surg Pathol. 2016 Aug;24(5):394-400
pubmed: 26912475
Nat Immunol. 2016 Feb;17(2):122-31
pubmed: 26784265
Expert Opin Ther Targets. 2020 May;24(5):417-426
pubmed: 32178549
Int J Neurosci. 2017 Mar;127(3):210-217
pubmed: 27050560
Mol Oncol. 2016 Jan;10(1):113-25
pubmed: 26433471
J Pathol. 2013 Oct;231(2):180-9
pubmed: 23775566
Int J Oncol. 2019 Sep;55(3):755-765
pubmed: 31322193
Cytokine. 2016 Jan;77:35-43
pubmed: 26520876
Hepatology. 2015 May;61(5):1627-42
pubmed: 25580681
Curr Gastroenterol Rep. 2017 Jan;19(1):2
pubmed: 28110453
Mol Cancer. 2018 Jan 18;17(1):10
pubmed: 29347950
Biochem Biophys Res Commun. 2014 Oct 24;453(3):486-92
pubmed: 25280997
Neoplasia. 2017 Sep;19(9):672-683
pubmed: 28772241
Oncol Lett. 2018 Jul;16(1):769-774
pubmed: 29963144
Oncoimmunology. 2012 Mar 1;1(2):229-231
pubmed: 22720252
Dig Dis Sci. 2015 May;60(5):1265-72
pubmed: 25655003
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Med Oncol. 2018 Nov 13;36(1):1
pubmed: 30426271
Med Oncol. 2017 Feb;34(2):23
pubmed: 28058630
Heliyon. 2018 Nov 26;4(11):e00971
pubmed: 30533546
Biochem Biophys Res Commun. 2016 Oct 21;479(3):461-468
pubmed: 27644880
Cytokine. 2012 Jun;58(3):368-79
pubmed: 22445500
Histopathology. 2018 Aug;73(2):259-272
pubmed: 29675965
Front Immunol. 2014 Apr 07;5:141
pubmed: 24778632
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463